Tissue | Expression Dynamics | Abbreviation |
Cervix | | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Colorectum (GSE201348) | | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Endometrium | | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
Liver | | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Prostate | | BPH: Benign Prostatic Hyperplasia |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00171574 | Cervix | CC | regulation of exocytosis | 39/2311 | 202/18723 | 2.90e-03 | 1.93e-02 | 39 |
GO:00068873 | Cervix | CC | exocytosis | 59/2311 | 352/18723 | 8.74e-03 | 4.48e-02 | 59 |
GO:0045921 | Colorectum | AD | positive regulation of exocytosis | 33/3918 | 86/18723 | 1.58e-04 | 2.20e-03 | 33 |
GO:0051047 | Colorectum | AD | positive regulation of secretion | 90/3918 | 310/18723 | 4.11e-04 | 4.66e-03 | 90 |
GO:1903532 | Colorectum | AD | positive regulation of secretion by cell | 82/3918 | 282/18723 | 6.85e-04 | 7.00e-03 | 82 |
GO:0006887 | Colorectum | AD | exocytosis | 96/3918 | 352/18723 | 2.48e-03 | 1.90e-02 | 96 |
GO:0017157 | Colorectum | AD | regulation of exocytosis | 59/3918 | 202/18723 | 3.20e-03 | 2.36e-02 | 59 |
GO:0099003 | Colorectum | AD | vesicle-mediated transport in synapse | 57/3918 | 200/18723 | 6.53e-03 | 4.06e-02 | 57 |
GO:00459211 | Colorectum | SER | positive regulation of exocytosis | 25/2897 | 86/18723 | 9.88e-04 | 1.17e-02 | 25 |
GO:00068871 | Colorectum | SER | exocytosis | 75/2897 | 352/18723 | 2.05e-03 | 2.03e-02 | 75 |
GO:00510471 | Colorectum | SER | positive regulation of secretion | 65/2897 | 310/18723 | 5.71e-03 | 4.19e-02 | 65 |
GO:00171571 | Colorectum | SER | regulation of exocytosis | 45/2897 | 202/18723 | 6.46e-03 | 4.63e-02 | 45 |
GO:19035321 | Colorectum | MSS | positive regulation of secretion by cell | 74/3467 | 282/18723 | 7.93e-04 | 8.36e-03 | 74 |
GO:00510472 | Colorectum | MSS | positive regulation of secretion | 80/3467 | 310/18723 | 8.55e-04 | 8.75e-03 | 80 |
GO:00990031 | Colorectum | MSS | vesicle-mediated transport in synapse | 54/3467 | 200/18723 | 1.94e-03 | 1.67e-02 | 54 |
GO:00459212 | Colorectum | MSS | positive regulation of exocytosis | 27/3467 | 86/18723 | 2.76e-03 | 2.17e-02 | 27 |
GO:0099504 | Colorectum | MSS | synaptic vesicle cycle | 48/3467 | 181/18723 | 4.85e-03 | 3.39e-02 | 48 |
GO:00990032 | Colorectum | FAP | vesicle-mediated transport in synapse | 51/2622 | 200/18723 | 1.09e-05 | 3.08e-04 | 51 |
GO:00995041 | Colorectum | FAP | synaptic vesicle cycle | 45/2622 | 181/18723 | 6.73e-05 | 1.28e-03 | 45 |
GO:0023061 | Colorectum | FAP | signal release | 94/2622 | 463/18723 | 1.06e-04 | 1.76e-03 | 94 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
CADPS2 | SNV | Missense_Mutation | novel | c.1023G>T | p.Gln341His | p.Q341H | Q86UW7 | protein_coding | tolerated(0.64) | possibly_damaging(0.453) | TCGA-AX-A2HC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | paclitaxel | PD |
CADPS2 | SNV | Missense_Mutation | | c.1090N>C | p.Ser364Pro | p.S364P | Q86UW7 | protein_coding | deleterious(0) | probably_damaging(0.986) | TCGA-AX-A3G9-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatin | SD |
CADPS2 | SNV | Missense_Mutation | rs187155107 | c.440N>A | p.Arg147Gln | p.R147Q | Q86UW7 | protein_coding | tolerated(1) | possibly_damaging(0.788) | TCGA-B5-A0JY-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicin | SD |
CADPS2 | SNV | Missense_Mutation | novel | c.1931N>A | p.Ala644Asp | p.A644D | Q86UW7 | protein_coding | tolerated(0.43) | probably_damaging(0.924) | TCGA-B5-A3FA-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
CADPS2 | SNV | Missense_Mutation | novel | c.1414N>C | p.Ser472Pro | p.S472P | Q86UW7 | protein_coding | tolerated(0.2) | benign(0.188) | TCGA-B5-A3FA-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
CADPS2 | SNV | Missense_Mutation | | c.1859A>G | p.Lys620Arg | p.K620R | Q86UW7 | protein_coding | tolerated(0.54) | benign(0.003) | TCGA-BG-A0VW-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
CADPS2 | SNV | Missense_Mutation | rs772238734 | c.1871G>A | p.Arg624His | p.R624H | Q86UW7 | protein_coding | deleterious(0.01) | possibly_damaging(0.454) | TCGA-BG-A222-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
CADPS2 | SNV | Missense_Mutation | rs371127285 | c.2981N>T | p.Ser994Leu | p.S994L | Q86UW7 | protein_coding | tolerated(0.22) | benign(0.017) | TCGA-BS-A0UF-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
CADPS2 | SNV | Missense_Mutation | | c.2442N>G | p.Asn814Lys | p.N814K | Q86UW7 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-D1-A103-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
CADPS2 | SNV | Missense_Mutation | | c.1913N>T | p.Pro638Leu | p.P638L | Q86UW7 | protein_coding | deleterious(0.01) | possibly_damaging(0.844) | TCGA-D1-A103-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |